Table 1. – Baseline clinical characteristics of the study population.
| Dipper group (n=46) | Non-dipper group (n=95) | p | |
|---|---|---|---|
| Age (years) | 61±12 | 61±11 | 0.868a |
| Male sex (n) (%) | 35 (76) | 72 (76) | 0.969a |
| BMI (kg/m2) | 27.4±3.8 | 28.0±3.7 | 0.395a |
| HT (n, %) | 23 (50) | 48 (51) | 0.953b |
| DM (n, %) | 12 (26) | 29 (31) | 0.586b |
| Smoking (n, %) | 14 (30) | 36 (38) | 0.385b |
| Mean daytime BP (mmHg, systolic/diastolic) | 121.3±13.9/ 73.4±9.2 | 118.2±15.4/ 69.5±10.3 | 0.251a 0.035a |
| Mean nighttime BP (mmHg, systolic/diastolic) | 103.5±12.3/ 63.0±8.2 | 118.2±15.4/ 70.5±9.8 | <0.001a <0.001a |
| ACS type: | |||
| STEMI (n, %) | 7 (15) | 34 (36) | 0.012b |
| NSTEMI (n, %) | 29 (63) | 56 (59) | 0.641b |
| USAP (n, %) | 10 (22) | 5 (5) | 0.030b |
| SYNTAX Score* | 5 (0-21) | 9.5 (0-29) | <0.001c |
| High SYNTAX Score (n, %) # | 16 (35) | 64 (67) | <0.001b |
| Medications | |||
| ACE inhibitor or ARB (n, %) | 16 (35) | 30 (32) | 0.704b |
| Calcium antagonist (n, %) | 6 (13) | 21 (22) | 0.200b |
| Diuretics (n, %) | 8 (17) | 17 (18) | 0.942b |
| MRA (n, %) | 1 (2) | 2 (2) | 0.979b |
| Β-blocker (n, %) | 10 (22) | 27 (28) | 0.398b |
| α-blocker (n, %) | 1 (2) | 0 (0) | 0.149b |
| Clopidogrel | 35(76.1) | 84(88) | 0.082 b |
| Ticagrelol | 8 (17) | 9 (9.5) | 0.180 b |
| Prasugrel | 3 (6.5) | 2(2.1) | 0.330 b |
| Acetylsalicylic acid | 46 (100) | 95 (100) | 1 b |
| Statin | 46 (100) | 93 (98) | 1 b |
a Independent t test, b Chi-square test, c Mann–Whitney U test, * Data are expressed as median (interquartile range) for continuous variables. #Above the median value. ACE: angiotensin converting enzyme; ACS: acute coronary syndrome; ARB: angiotensin receptor blocker; BMI: body mass index; BP: blood pressure; DM: diabetes mellitus; HT: hypertension; MRA: mineralocorticoid receptor antagonist; NSTEMI: non-ST-elevation myocardial infarction; STEMI: ST-elevation myocardial infarction; USAP: unstable angina pectoris.